Differential nucleobase protection against 5-fluorouracil toxicity for squamous and columnar cells: implication for tissue function and oncogenesis John P. Vanden HeuvelJerry T. ThompsonJohn P. Ford PRECLINICAL STUDIES Open access 01 July 2015 Pages: 1003 - 1011
P-glycoprotein and breast cancer resistance protein restrict the brain penetration of the CDK4/6 inhibitor palbociclib Mark C. de GooijerPing ZhangOlaf van Tellingen PRECLINICAL STUDIES 01 July 2015 Pages: 1012 - 1019
Chloroquine inhibits the malignant phenotype of glioblastoma partially by suppressing TGF-beta Laurent-Olivier RoyMarie-Belle PoirierDavid Fortin PRECLINICAL STUDIES 15 August 2015 Pages: 1020 - 1031
Subcellular localization of anthracyclines in cultured rat cardiomyoblasts as possible predictors of cardiotoxicity Kazimierz StudzianKrzysztof KikLeszek Szmigiero PRECLINICAL STUDIES Open access 14 August 2015 Pages: 1032 - 1039
Phase I study of the mTOR inhibitor ridaforolimus and the HDAC inhibitor vorinostat in advanced renal cell carcinoma and other solid tumors Matthew ZibelmanYu-Ning WongElizabeth R. Plimack PHASE I STUDIES 20 June 2015 Pages: 1040 - 1047
First-in-human study of the toxicity, pharmacokinetics, and pharmacodynamics of CG200745, a pan-HDAC inhibitor, in patients with refractory solid malignancies Kyu-pyo KimSeong Joon ParkTae Won Kim PHASE I STUDIES 17 June 2015 Pages: 1048 - 1057
A phase I/Ib study of trametinib (GSK1120212) alone and in combination with gemcitabine in Japanese patients with advanced solid tumors Akiyoshi KasugaKazuhiko NakagawaJunji Furuse PHASE I STUDIES 12 August 2015 Pages: 1058 - 1067
Phase I study of TAS-102 and irinotecan combination therapy in Japanese patients with advanced colorectal cancer Toshihiko DoiTakayuki YoshinoAtsushi Ohtsu PHASE I STUDIES Open access 12 July 2015 Pages: 1068 - 1077
Phase 1 dose de-escalation trial of the endogenous folate [6R]-5,10-methylene tetrahydrofolate in combination with fixed-dose pemetrexed as neoadjuvant therapy in patients with resectable rectal cancer Bengt GustavssonGöran CarlssonFernando Gibson PHASE I STUDIES Open access 21 July 2015 Pages: 1078 - 1085
Phase 1 study of APTO-253 HCl, an inducer of KLF4, in patients with advanced or metastatic solid tumors Andrea CercekJennifer WhelerLeonard Saltz PHASE I STUDIES 14 August 2015 Pages: 1086 - 1092
Phase I trial of combination of FOLFIRI and pasireotide, a somatostatin analogue, in advanced gastrointestinal malignancies Amit MahipalDave ShibataRichard Kim PHASE I STUDIES 16 August 2015 Pages: 1093 - 1099
A phase I study of VS-6063, a second-generation focal adhesion kinase inhibitor, in patients with advanced solid tumors Suzanne F. JonesLillian L. SiuGeoffrey I. Shapiro PHASE I STUDIES 04 September 2015 Pages: 1100 - 1107
Phase II study of tivantinib (ARQ 197) in patients with metastatic triple-negative breast cancer Sara M. TolaneySally TanIan E. Krop PHASE II STUDIES Open access 01 July 2015 Pages: 1108 - 1114
Topotecan plus cyclophosphamide in adults with relapsed or refractory pediatric-type sarcoma: a retrospective analysis from the German Sarcoma Medical Oncology Group (AIO) Jörg Thomas HartmannR. D. IsselsI. Sturm SHORT REPORT 12 July 2015 Pages: 1115 - 1122
Evaluation of cytotoxic activity of titanocene difluorides and determination of their mechanism of action in ovarian cancer cells Lucie KoubkovaRostislav VyzulaRoman Hrstka SHORT REPORT 24 July 2015 Pages: 1123 - 1132
Ulcerative colitis in a patient with non-small-cell lung cancer receiving bevacizumab Midori TanakaHidenobu IshiiTomoaki Hoshino SHORT REPORT 18 August 2015 Pages: 1133 - 1135
BRAF-mutated clear cell sarcoma is sensitive to vemurafenib treatment Svetlana A. ProtsenkoAnna I. SemionovaEvgeny N. Imyanitov SHORT REPORT 20 August 2015 Pages: 1136 - 1143
Long term exposure to antiangiogenic therapy, bevacizumab, induces osteonecrosis Tessa TabouretThomas GregoryRomain Coriat SHORT REPORT 28 August 2015 Pages: 1144 - 1147
Severe acute interstitial lung disease in a patient with anaplastic lymphoma kinase rearrangement–positive non–small cell lung cancer treated with alectinib Yuzo YamamotoIsamu OkamotoYoichi Nakanishi SHORT REPORT 04 September 2015 Pages: 1148 - 1150